Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 3/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282201 | 0.83 | MAN1B1 (0.38) | GAAALDH1A1MAPT | |
| SCHEMBL4281787 | 0.79 | MEN1 (0.41) | MEN1KMT2APOLBGRIN2BTSHR | |
| SCHEMBL4293573 | 0.77 | SMN1; SMN2 (0.37) | MEN1KMT2APOLBGRIN2BGAA | |
| SCHEMBL4292964 | 0.74 | MAPT (0.45) | KMT2APOLBALDH1A1KDM4EMAPT | |
| SCHEMBL4287930 | 0.73 | F10 (0.38) | GAAMAPT | |
| SCHEMBL4295533 | 0.72 | ATM (0.43) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4281547 | 0.72 | KMT2A (0.41) | MEN1KMT2APOLBTSHRGAA | |
| SCHEMBL4286525 | 0.72 | RAB9A (0.47) | MEN1KMT2APOLBGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL7692015 | 0.70 | OPRK1 (0.52) | RBP4KDM4E | |
| SCHEMBL4292160 | 0.70 | MAOA (0.47) | MEN1KMT2AGAAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MEN1 1254/4885KMT2A 1049/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.